Company Overview

BullFrog AI Holdings, Inc. is a biotechnology and artificial intelligence company focused on improving drug development and clinical trial outcomes through machine learning and advanced analytics. The company operates at the intersection of the biopharmaceutical, healthcare technology, and data analytics industries, using proprietary AI-driven platforms to analyze complex biomedical and clinical datasets. Its primary business model centers on licensing and applying its analytical technology to pharmaceutical and biotechnology companies seeking to enhance drug discovery, patient stratification, and clinical development decision-making.

The company’s core technology platform was derived from research conducted at the Johns Hopkins University Applied Physics Laboratory, which contributed to BullFrog AI’s positioning in AI-enabled precision medicine and drug development analytics. BullFrog AI has evolved from a data analytics-focused biotechnology company into a publicly traded organization emphasizing AI-assisted therapeutic development and biomarker discovery. Public filings and investor materials indicate that the company seeks to differentiate itself through explainable AI models designed to identify hidden relationships in clinical and genomic datasets that may improve the probability of regulatory and commercial success for therapeutics.

Business Operations

BullFrog AI primarily generates revenue through collaborations, technology licensing arrangements, analytics services, and internally developed therapeutic programs supported by its AI platform. The company’s operations focus on applying machine learning algorithms and predictive analytics to drug development processes, including patient response prediction, biomarker identification, and optimization of clinical trial design. Its principal platform, commonly referenced in company disclosures as the bfLEAP™ analytics platform, is designed to process heterogeneous biomedical datasets and uncover patterns that may not be readily identifiable through conventional statistical methods.

The company operates primarily in the United States, with activities concentrated in biotechnology research and strategic partnerships within the pharmaceutical and healthcare sectors. BullFrog AI has also disclosed involvement in therapeutic development initiatives and collaborations related to oncology and other disease areas. Publicly available filings indicate that the company maintains relationships with academic and research institutions, including technology licensing arrangements tied to intellectual property originating from the Johns Hopkins University Applied Physics Laboratory. Data regarding large-scale international subsidiaries or major global joint ventures remains limited in publicly available disclosures.

Strategic Position & Investments

BullFrog AI’s strategic direction centers on expanding the commercial adoption of AI-driven analytics in precision medicine and biopharmaceutical development. The company has emphasized growth through strategic collaborations, internal therapeutic pipeline development, and expansion of its AI platform capabilities. Public disclosures indicate a focus on leveraging machine learning to reduce development risk in drug programs by improving clinical trial efficiency and identifying responsive patient populations. The company has also highlighted oncology and immune-related conditions as areas of strategic interest.

In addition to platform commercialization, BullFrog AI has pursued investments in proprietary and partnered therapeutic assets intended to demonstrate the utility of its analytics technology in real-world drug development settings. Company filings and investor communications reference ongoing efforts to broaden the application of the bfLEAP™ platform across additional therapeutic categories and external partnerships. While BullFrog AI has announced collaborations and licensing activities, publicly available information regarding large-scale acquisitions or diversified subsidiary holdings remains limited. Data inconclusive based on available public sources regarding material international portfolio investments.

Geographic Footprint

BullFrog AI is headquartered in Gaithersburg, Maryland, and its operations are primarily concentrated in the United States. The company’s activities are closely tied to the U.S. biotechnology ecosystem, including collaborations involving academic research institutions, pharmaceutical companies, and healthcare technology stakeholders. Its operational footprint appears focused on North American markets, particularly in relation to AI-enabled drug development and clinical analytics services.

Although BullFrog AI’s technology may have applicability in global pharmaceutical markets, publicly available filings do not indicate a broad multinational operating infrastructure comparable to larger biotechnology companies. The company’s strategic influence is principally linked to partnerships and technology applications within the global life sciences sector rather than extensive physical international operations. Data inconclusive based on available public sources regarding material operational facilities outside the United States.

Leadership & Governance

BullFrog AI’s leadership team includes executives with backgrounds spanning biotechnology, pharmaceuticals, healthcare analytics, and technology commercialization. The company’s governance and strategic direction emphasize the integration of artificial intelligence into drug development workflows, with management communications frequently highlighting data-driven precision medicine and improved clinical decision-making as central objectives.

Key executives identified in public filings and corporate materials include:

• Vin Singh – Chief Executive Officer
• Anand Kumar – Chief Financial Officer
• Dr. Eric Leire – Chief Operating Officer
• Dr. Michael P. Weiner – Chief Medical Officer

Public company disclosures, including SEC filings, indicate that leadership strategy is focused on expanding the commercial utility of the company’s AI platform, building biopharmaceutical partnerships, and advancing internally supported therapeutic opportunities. Governance oversight is conducted through the company’s board of directors and executive management structure consistent with publicly traded biotechnology companies listed on U.S. securities markets.